Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus

Thrombosis and Haemostasis

Volumn 76, Issue 1, 1996, Pages 34-37

  Davì, Giovanni ^a,c   Belvedere, Mario ^a,b   Vigneri, Sergio ^a   Catalano, Isabella ^a,b   Giammarressi, Carlo ^a,b   Roccaforte, Salvatore ^a   Consoli, Agostino ^a   Mezzetti, Andrea ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ematologia ^*

^c Ematologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ANTIGEN; GLIPIZIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOXANE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC ANGIOPATHY; FEMALE; HUMAN; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 0030055521     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650518     Document Type: Article

References (27)

1. Mustard JF, Packham MA. Platelets and diabetes mellitus. N Engl J Med 1984; 311: 665-7.
2. Nathan MD. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-85.
3. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-43.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-9.
6. Lasker RD. The diabetes control and complication trial. Implications for Policy and Practice. N Engl J Med 1993; 329: 1035-6.
7. Auwerk J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
8. Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
9. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA. Platelet plasminogen activator inhibitor I in patients with type II diabetes. Diabetes Care 1994; 171: 818-23.
10. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-901.
11. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57
12. 2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-7.
13. Siegel S. Nonparametric Statistics for the Behavioral Sciences. Mc Graw-Hill Book Co: New York 1986; p 184.
14. Patrono C, Davì G. Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes Metab Rev 1993; 9: 177-88.
15. Davì G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb 1993; 13: 1346-9.
16. Di Minno G, Silver MJ, Cerbone AM, Riccardi G, Rivellese A, Mancini M, Thiagarajan P. Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane. Blood 1985; 65: 156-62.
17. Mayfield RK, Halushka PV, Wohltmann HJ, Lopes-Virella MF, Chambers JK, Loadholt CB, Colwell JA. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes 1985; 34: 1127-33.
18. Davì G, Averna M, Catalano I, Barbagallo CM, Giovenco E, Carroccio A, Notarbartolo A, Strano A. Platelet function in patients with type II diabetes mellitus: the effect of glycaemic control. Diabetes Res 1989; 10: 7-12.
19. Kudlacek S, Schernthaner G. The effect of insulin treatment on HbAlc, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five-year follow-up study. Horm Metab Res 1992; 24: 455-500.
20. Genuth S. Insulin use in NIDDM. Diabetes Care 1990; 13: 1240-64.
21. Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications: an epidemiological perspective. Diabetes Care 1992; 15: 1141-55.
22. Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler S. Long term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Diabetes Care 1994; 17: 45-9.
23. Ozaky Y, Yatoni Y, Kume S. Effects of oral hypoglycaemic agents on platelet functions. Biochem Pharmacol 1992; 44: 687-91.
24. Vukovich T, Proidl S, Knobl P, Teufelsbauer H, Schnack C, Schernthaner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost 1992; 68: 253-6.
25. Knobl P, Schenhahaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 1994; 71: 692-7.
26. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-4.
27. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-8.